changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
London, UK, 09 June 2016
BTG, a global leader in interventional oncology, announced today that it has joined the Global Liver Institute’s Partnership Network as a founding member. The Global Liver Institute (GLI) is the innovation and collaboration platform for the liver community worldwide. BTG will provide expertise and support on key initiatives to help transform care for liver cancer patients.
GLI’s portfolio of liver cancer initiatives includes the Reimagine Liver Cancer stakeholder workshop, the HCC360 Registry & Biorepository, and the Personalized Medicine in Liver Diseases meeting.
GLI established the Partnership Network in January 2016 to bring together like-minded organizations and individuals to fundamentally transform advocacy in the liver field. The Partnership Network addresses the need for initiatives that cross disciplines, sectors, and stakeholder groups to advance patient-centered research, education, and health system delivery solutions.
“We are delighted to welcome BTG to our Partnership Network. Their knowledge and experience in the complexities of liver cancer care will be an important contribution to the Partnership Network” stated Donna R. Cryer, JD, President, & CEO of the Global Liver Institute. “According to the most recent data, liver cancer is the second most deadly cancer worldwide and one of the few cancers that is rising in incidence.”
BTG’s interventional oncology portfolio is transforming the way cancer is being treated by discovering and developing differentiated therapeutic innovations for hard to treat primary and secondary liver cancers. The BTG interventional oncology portfolio offers the flexibility to treat patients through embolization and internal radiation, with minimally invasive treatments that go precisely where they are needed. BTG is also conducting research in these areas to extend the reach of science and technology over liver disease.
Ken Pugh, BTG Vice President, Commercial Development and Interventional Oncology Marketing, the Americas remarked, “We are excited to come on board as a founding member of the Global Liver Institute Partnership Network. BTG is committed to improving patient outcomes by delivering continued advancements in personalized, loco-regional cancer therapies. We believe passionately that interventional oncology has the power to improve human health and our partnership with the GLI will help to build connections across the liver community to transform cancer care.”
GLI and BTG call for more public attention to liver cancer, mechanisms that promote earlier diagnosis, increased transparency and education on the dangers of cumulative risk factors for liver cancer, assistance for patients and families navigating the liver cancer care journey, and the need for increased participation in research.
The GLI board includes renowned liver cancer experts Lewis R Roberts, MB, ChB, PhD of Mayo Clinic and Melanie Thomas, MS, MS at the Gibbs Cancer Center & Research Institute, the founder of CanLiv, the Hepatobiliary Cancers Foundation now part of GLI.
About The Global Liver Institute
The Global Liver Institute is a 501(c)(3) tax exempt not-for-profit organization, headquartered in Washington, D.C., United States. Our Vision is for liver health to take its place on the global public health agenda commensurate with its prevalence and impact. Our Mission is to improve the impact of the liver community by promoting innovation, collaboration, and scaling optimal approaches to eradicating liver diseases.
About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins. To learn more about BTG Interventional Medicine, please visit: btg-im.com.
Donna Cryer, President & CEO
Tel: +1 (202) 603-3493
Chris Sampson, Corporate Communications Director
Tel: +44 20 7575 1595;
Mobile: +44 7773 251
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com